R T Joffe1, D R Schuller. 1. Mood Disorders Program, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
Abstract
BACKGROUND: We evaluated the efficacy of buspirone in the augmentation of antidepressant response to the serotonin reuptake inhibitors. METHOD: Twenty-five patients with major depressive disorder who had failed several previous treatments for their current depressive episode were included. After failing a trial of fluoxetine or fluvoxamine, they received buspirone in addition to the serotonin reuptake inhibitor for 3 weeks in an open clinical trial. RESULTS: Seventeen of 25 patients had a marked or complete antidepressant response. CONCLUSION: These data provide clinical evidence suggesting that buspirone augmentation may be useful clinical alternative in depressed patients who fail to respond to a serotonin reuptake inhibitor.
BACKGROUND: We evaluated the efficacy of buspirone in the augmentation of antidepressant response to the serotonin reuptake inhibitors. METHOD: Twenty-five patients with major depressive disorder who had failed several previous treatments for their current depressive episode were included. After failing a trial of fluoxetine or fluvoxamine, they received buspirone in addition to the serotonin reuptake inhibitor for 3 weeks in an open clinical trial. RESULTS: Seventeen of 25 patients had a marked or complete antidepressant response. CONCLUSION: These data provide clinical evidence suggesting that buspirone augmentation may be useful clinical alternative in depressedpatients who fail to respond to a serotonin reuptake inhibitor.
Authors: Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf Journal: CNS Drugs Date: 2004 Impact factor: 5.749